510(k) device
Eye-Sync
Syncthink, Inc. · Brain Injury Adjunctive Interpretive Oculomotor Assessment Aid (QEA, Class II) · First FDA decision Oct 2, 2021, newest Oct 2, 2021Traumatic brain injury and concussion
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
5
Naming "Eye-Sync"
MAUDE reports
0
Brand "Eye-Sync", since 2015
PubMed studies
3
Mentioning "Eye-Sync"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eye-Sync
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EYE-SYNCBreakthrough510(k)
K202927 · Decided Oct 2, 2021 · 368 days after receipt
Device type: Brain Injury Adjunctive Interpretive Oculomotor Assessment Aid (QEA) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Eye-Sync", any status and sponsor, newest update first.
- Ocular-vestibular Biomarker Identification for ADHDStatus unknown
Sync-Think, Inc.Not on our public-company list
NCT04504890 · 240 participants (planned) · Start Jul 16, 2020 · Primary completion Aug 5, 2021
Device: EYE-SYNC · For: ADHD - Combined Type; ADHD; ADHD Predominantly Inattentive Type and 1 more
Sites: San Carlos, California
- Trial of Hoya SYNC III Design LensesCompleted
The Institute of Optometry, LondonAcademic, hospital or other
NCT03831919 · 90 participants · Start Jan 7, 2019 · Primary completion Jun 30, 2020
Device: SYNC III; single vision lenses · For: Computer Vision Syndrome
Sites: Alicante, Spain; London, United Kingdom
Sync-Think, Inc.Not on our public-company list
NCT04381767 · 1,303 participants · Start Dec 19, 2018 · Primary completion Mar 23, 2020
Device: EYE-SYNC · For: Concussion, Mild; Concussion; Eye; Concussion, Brain and 3 more
Sites: Palo Alto, California
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eye-Sync", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QEA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2114-2025 · Started Sep 19, 2023 · Posted by FDA Jul 11, 2025
Reason given: Eye syncing issues causing the device to be inoperable. Unable to be repaired due to discontinuation of support for the Pico 2 platform, which was no longer in production or serviceable as of August 31, 2023.
Cause as FDA categorized it: Device Design · Device type: Brain Injury Adjunctive Interpretive Oculomotor Assessment Aid (QEA)
Published research
The most relevant PubMed records for "Eye-Sync"[tiab]. The summary above synthesizes these.
- Diagnostic accuracy and reliability of sideline concussion evaluation: a prospective, case-controlled study in college athletes comparing newer tools and established tests.
Harmon KG, Whelan BM, Aukerman DF, et al. · Br J Sports Med · 2022
- Comparative Performance of Three Eye-Tracking Devices in Detection of Mild Traumatic Brain Injury in Acute Versus Chronic Subject Populations.
King J, Friend C, Zhang D, et al. · Mil Med · 2024Comparative Study, Research Support, U.S. Gov't, Non-P.H.S.
- Reliable sideline ocular-motor assessment following exercise in healthy student athletes.
Sundaram V, Ding VY, Desai M, et al. · J Sci Med Sport · 2019
Other devices of this type
Also filed under product code QEA.
- EyeBOX (Model EBX-4)Oculogica, Inc. · De Novo 2021
- EyeBOX SNAPOculogica, Inc. · 510(k) 2026
- EyeBOX EBX-4.1Oculogica, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.